Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Great Novel Therapeutics Biotech & Medicals's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.42.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Great Novel Therapeutics Biotech & Medicals's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 8.80.
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Great Novel Therapeutics Biotech & Medicals's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Great Novel Therapeutics Biotech & Medicals's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Great Novel Therapeutics Biotech & Medicals Days Inventory Related Terms
Great Novel Therapeutics Biotech & Medicals Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Great Novel Therapeutics Biotech & Medicals Days Inventory Chart
Great Novel Therapeutics Biotech & Medicals Annual Data
ROCO:7427 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Great Novel Therapeutics Biotech & Medicals Days Inventory vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) has a Days Inventory of 436.11 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Great Novel Therapeutics Biotech & Medicals and its competitors. This is 73% below median its historical median of 1,643.17. Over the past decade, Great Novel Therapeutics Biotech & Medicals' Days Inventory has ranged from 75.52 to 52,296.86. According to the industry distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #552 out of 638 companies in the Biotechnology industry, placing it in the top 86.5%.
Is Great Novel Therapeutics Biotech & Medicals' Days Inventory too high?
Great Novel Therapeutics Biotech & Medicals' current Days Inventory of 436.11 is 73% below median its 10-year median of 1,643.17. Over the past 10 years, this metric has ranged from a low of 75.52 to a high of 52,296.86. The Biotechnology industry median Days Inventory is 183.20. Great Novel Therapeutics Biotech & Medicals' value of 436.11 is 138.1% above this industry median. Based on the distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #552 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Great Novel Therapeutics Biotech & Medicals has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Great Novel Therapeutics Biotech & Medicals' Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Great Novel Therapeutics Biotech & Medicals ranks #552 out of 638 companies for Days Inventory. This places Great Novel Therapeutics Biotech & Medicals in the lower half of its industry. The industry median Days Inventory is 183.20. Great Novel Therapeutics Biotech & Medicals' value of 436.11 is 138.1% above this benchmark. Historically, Great Novel Therapeutics Biotech & Medicals' own Days Inventory has ranged from 75.52 to 52,296.86 over the past decade. While the company's 10-year median is 1,643.17 vs. the industry median of 183.20, Great Novel Therapeutics Biotech & Medicals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Great Novel Therapeutics Biotech & Medicals's current Days Inventory of 436.11 is 138.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Great Novel Therapeutics Biotech & Medicals and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Great Novel Therapeutics Biotech & Medicals's current Days Inventory is 436.11, which is 73% below median its own 10-year median of 1,643.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Great Novel Therapeutics Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals (ROCO:7427) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$25.79, compared to a current price of NT$68.20 — trading 164.4% above its estimated fair value. The current Days Inventory is 436.11, which is 73% below median its 10-year median of 1,643.17 and 138.1% above the Biotechnology industry median of 183.20. Great Novel Therapeutics Biotech & Medicals' overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Great Novel Therapeutics Biotech & Medicals (ROCO:7427), the current Days Inventory is 436.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Overvalued in 2026?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals stock appears to be overvalued.
The current stock price of NT$68.20 is trading 164.4% above its estimated GF Value™ of NT$25.79.
GuruFocus considers Great Novel Therapeutics Biotech & Medicals to be Significantly Overvalued.
Key valuation signals for ROCO:7427:
Days Inventory: 436.11 (73% below median its 10-year median of 1,643.17)
GF Value™: NT$25.79 vs. price of NT$68.20 (164.4% above fair value)
Industry Position: 138.1% above the Biotechnology median (#552 of 638)
No single metric tells the full story. See the ROCO:7427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Great Novel Therapeutics Biotech & Medicals Business Description
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
43GF Score
Get the complete analysis for ROCO:7427
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7427 has been successfully added to your 
